Multiple sclerosis is a disease in which the immune system damages the brain and spinal cord.
This damage affects myelin, the protective layer surrounding nerves, which disrupts signals that control movement, sensation and thinking.
IMX39 is designed to work earlier in the disease process than many existing treatments.
In addition to reducing immune-driven damage, it may also support repair of the protective myelin around nerves.
In animal models of MS, IMX39 reduced disease symptoms, preserved movement and showed evidence of repairing nerve insulation.
IMX39 is currently being prepared for clinical trials in people.
If you are living with MS and looking for support, there are a number of trusted organisations across Australia that provide information, advocacy and practical assistance.
MS Australia offers national information, research updates and links to state-based services
Visit website
MS Plus (covering NSW, ACT, VIC and TAS) and MSWA provide local support including NDIS guidance, allied health services, peer groups and wellbeing programs.
Visit website
